Investors
Digital Health Investment Intelligence & Due Diligence
Build a sharper investment thesis, assess opportunities against relevant peers, and expose the commercial, clinical, and execution risks hidden beneath market momentum.
Define categories, market structure, capital flows, maturity, exits, and the signals shaping an investable thesis.
Test company claims against peers, customers, partnerships, clinical evidence, regulation, and execution history.
Monitor exposure, evidence progression, market change, and risk across a digital health portfolio.
The decision context
Healthtech due diligence requires market context that the data room cannot provide
Digital health sits across software, care delivery, life sciences, medical devices, regulation, and enterprise procurement. Market labels are inconsistent, private-company evidence is uneven, and funding can obscure rather than confirm durable quality.
Galen Growth gives investors an independent view of category structure, competitive position, commercial traction, clinical evidence, partnership quality, organisational maturity, and exit context. The analysis is tailored to the investment thesis and the risks that could change it.
What Galen Growth evaluates
Intelligence from thesis formation through portfolio monitoring
Each engagement starts with the decision, then brings together the market, company, clinical, partnership, and execution evidence required to answer it.
Digital health investment research
Structure a category, quantify its activity, identify value pools, and distinguish persistent change from market noise.
Explore capability →02Commercial due diligence
Test market claims, competitive position, customer quality, partnership traction, and realistic growth assumptions.
Explore capability →03Healthcare startup benchmarking
Build a relevant peer set and compare maturity, evidence, commercial traction, capital, and strategic position.
Explore capability →04Portfolio risk analysis
Identify concentration, evidence gaps, dependencies, and action priorities across portfolio companies.
Explore capability →05Market and exit intelligence
Track funding, consolidation, acquirer behaviour, hold periods, and category-level exit patterns.
Explore capability →06Opportunity sourcing
Find companies matching a defined category, geography, evidence, maturity, and investment profile.
Explore capability →Powered by HealthTech Alpha
Independent company evidence within a defensible peer context
HealthTech Alpha combines proprietary maturity measures with underlying records for funding, partnerships, clinical evidence, regulation, team, and market activity. Galen Growth uses those records to challenge the investment story and explain why a target appears strong or exposed.
Explore HealthTech Alpha- Custom peer sets
- Commercial and partnership evidence
- Clinical and regulatory signals
- Portfolio and exit context
Methodology
From strategic question to accountable action
- Define the thesis
Identify the market, company, and execution assumptions that would materially change the decision.
- Build the peer context
Select comparables by category, customer, business model, geography, and maturity.
- Test observable evidence
Compare claims with commercial, clinical, regulatory, organisational, and ecosystem signals.
- Report decision-critical findings
Separate confirmed strengths, unresolved questions, material risks, and post-investment priorities.
Relevant work
How Galen Growth has supported related decisions
Mapping the Real-World Evidence Landscape in China for an Investor Thesis
Enabled the investor to move from thesis hypothesis to targeted diligence on a short list of category leaders.
Read case study →Case studyCompetitive analysis in genomics for a reinsurance company
The Corporate Venture Capital (CVC) arm of a global reinsurance company wanted to, as part of their ongoing due diligence, undertake a global competitive analysis in the genomics space before committing to their selected investment target.
Read case study →Case studyMacro and micro-environment analysis in RWD & RWE
The Corporate Venture Capital (CVC) arm of a global pharmaceutical company wanted to analyse a specific key APAC market to assess both the macro and micro-environment for Real World Data and Real Word Evidence to inform corporate strategy and prioritise key ventures for further engagement. By utilising Galen Growth's proven PlayBook methodology, we enabled our client to fully understand the RWD and RWE innovation environment and readiness to enable the identification and prioritisation of Digital Health ventures with the right capabilities and achievements. Further prioritisation driven by Deep Dive analysis of select ventures, to map their operating model, leading to direct engagement with their leadership team. The examination covered 1 key therapeutic area in 1 key APAC country. We screened 15 ventures and, in collaboration with our client, shortlisted 7.
Read case study →Related intelligence
Research for this decision context
Explore Galen Growth analysis and reports built from the same digital health evidence base.
FAQ
Common questions
What is digital health investment intelligence?
It is structured market, company, competitor, evidence, funding, partnership, and exit intelligence used to support investment theses, sourcing, due diligence, and portfolio decisions.
How is digital health due diligence different from general technology diligence?
It must account for clinical evidence, regulation, healthcare workflows, reimbursement, enterprise adoption, patient impact, and category-specific maturity alongside commercial and technical factors.
Can Galen Growth support portfolio monitoring?
Yes. We can establish a consistent evidence model and monitor company, competitor, category, partnership, and risk signals over time.
Who we help